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The exact prevalence of food allergy in the general population is unknown, but almost 12% of pediatric population
refers a suspicion of food allergy. IgE mediated reactions to food are actually the best-characterized types of allergy,
and they might be particularly harmful especially in children. According to the “hygiene hypothesis” low or no
exposure to exogenous antigens in early life may increase the risk of allergic diseases by both delaying the
development of the immune tolerance and limiting the Th2/Th1 switch. The critical role of intestinal microbiota in
the development of immune tolerance improved recently the interest on probiotics, prebiotics, antioxidants,
polyunsaturated fatty acid, folate and vitamins, which seem to have positive effects on the immune functions.
Probiotics consist in bacteria or yeast, able to re-colonize and restore microflora symbiosis in intestinal tract. One of
the most important characteristics of probiotics is their safety for human health. Thanks to their ability to adhere to
intestinal epithelial cells and to modulate and stabilize the composition of gut microflora, probiotics bacteria may
play an important role in the regulation of intestinal and systemic immunity. They actually seem capable of
restoring the intestinal microbic equilibrium and modulating the activation of immune cells.
Several studies have been recently conducted on the role of probiotics in preventing and/or treating allergic
disorders, but the results are often quite contradictory, probably because of the heterogeneity of strains, the
duration of therapy and the doses administered to patients. Therefore, new studies are needed in order to clarify
the functions and the utility of probiotics in food allergies and ion other types of allergic disorders.
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Food allergy is an immunological disease that may have
a high impact on the quality of life of both patients and
their relatives, with economic consequences for the pa-
tients and the NHS (National Health Service). Even if
the exact prevalence is not known, almost 20% of popu-
lation refers several symptoms that can be related to
food allergy, and most of them end up eliminating some
food from the diet with a loss of nutritional balance.
Such a situation may become particularly harmful espe-
cially in pediatric patients, because they might experience
several clinical symptoms, but also because the restricted
diet, recommended until the allergy work up is completed,
could lead to possible nutritional deficiencies.
In recent years many studies focused on the compre-
hension of molecular and immunological mechanism of* Correspondence: leonardi@unict.it
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reproduction in any medium, provided the orallergic response and, in particular, it has been demon-
strated the importance of gut microbiota for the main-
tenance not only of intestinal physiology, but also for
the correct development of the immune system and the
induction of oral tolerance.
Growing evidence indicates that dietary factors as
probiotics, prebiotics, antioxidants, polyunsaturated fatty
acid, folate and vitamins have positive effects on the im-
mune functions. In particular probiotic strains show the
ability to restore intestinal microbic equilibrium and
modulate activation of immune cells and can explain the
gradually diffusion of probiotics in clinical practice and
in allergy treatment.Food hypersensitivity
The term “food hypersensitivity” is referred to any patho-
logical manifestation related to food ingestion: these reac-
tions can be mainly divided into “food intolerances” and
“food allergies”, according to the molecular mechanism
of action.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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types of allergy; non-IgE mediated reactions or cell medi-
ated responses include those reactions in which specific
cells, different from mastocytes (and basophils), are re-
sponsible for the allergic reaction, and they mostly involve
the gastrointestinal tract; mixed IgE mediated and cell me-
diated responses are those reactions in which both IgEs
and immune cells are involved [1-4].
Other pathological conditions associated with symp-
toms similar to food allergy include pseudo-food allergy,
in which, even though the clinical picture is the same
that can be detected in allergic hypersensitivities, no im-
munological mechanism can be demonstrated.
The exact prevalence of food allergy in the general
population is yet unknown. According to different meta-
analysis [5,6], almost 12% of pediatric population refers
a suspicion of food allergy and in Italy, about 10% of
parents believe that their children suffer from food allergy
[7]. However, the prevalence of food allergy is about 3%
when the diagnosis is based on oral food challenge, that is
the “gold standard [8,9].
Recent studies showed that, in the United States, the
prevalence of food allergy is of almost 5% of children
younger than 3, while the disease affects almost 4% of the
adult population. Recently, Sicherer and Sampson showed
a different prevalence of food allergy, stating it might inter-
est up to 6-10% of the general population, with differences
due to geographic distribution, age and ethnicity [10].
In Europe, the prevalence of food allergy is 1-2% in the
adult population and 5-8% in children, even if these data
are underestimated, because of the lack of good quality
publications and of the different “in vitro” and “in vivo”
diagnostic approaches of the different studies. Moreover,
even thought the EAACI ha tried to standardize the al-
lergy work-up for food allergies, challenges differ from
one center to another, and many different specialists (pe-
diatricians, allergists, gastroenterologists, dermatologists)
seem to show different approaches to the disease.
The other datum that has to be considered as clearly
established, is that the prevalence of food allergy is
higher during the first years of life, with an estimated in-
cidence between 6 and 8% before the age of 2. Clinicians
may therefore assist to a progressive decrease of food
allergies over time, as patients grow up.
The increasing immigration in Italy of children coming
from different countries has brought up the issue on
whether they might change the prevalence of the disease
in our Country. Nevertheless, a retrospective study con-
ducted between 1999 and 2001 in 23 Italian Pediatric
Clinics in Italy showed that children of immigrant fam-
ilies who were born in Italy or who arrived in Italy dur-
ing the first years of life, show the same incidence of
food allergy as Italian children, with, therefore, an in-
crease of the overall prevalence [11].Most of cutaneus allergic reactions to food are due to
the role of allergen specific IgE antibodies with their
high affinity receptors (FceRI), expressed on mast cells
and basophils, and low affinity receptors (FceRII), ex-
pressed on macrophages, monocytes, lymphocytes and
platelets. The linkage of IgE with FceRI leads to receptor
crosslinking and release of cellular mediators [12,13].
The amount of potentially dangerous foods is quite
low (egg, milk, peanut, tree nuts, fish, shellfish, wheat
and soy) and their allergenicity is due to the their proteic
component. The “major” allergenic segments or “epi-
topes” of these proteins are water-soluble glycoproteins
with a molecular weight usually comprised between 10
and 70 Kd and a good resistance to heat and acid and
proteasic digestion. In addition, the presence of immuno-
stimulatory factors in the food may also contribute to such
a sensitization [14,15].
Usually, only the minority of subjects exposed to a
food allergen develops an allergic response. In fact, the
list of food mentioned above includes products that are
commonly ingested by almost the entire population,
while allergic symptoms appear only in a small percent-
age of persons. The biochemical characteristics of food
allergens cannot indeed explain alone its allergenicity,
but the allergic response is also due to specific genetic
or epigenetic characteristics of the subject. Even though
no specific genes responsible of allergic reactions have
been firmly identified so far, it is widely accepted, in
clinical practice, that atopy (defined as a personal or fa-
milial tendency to produce IgE antibodies in response
to low doses of allergens) [1] relates to a certain predis-
position to develop food allergy as well. The natural re-
sponse after exposure to new food allergens is known
as tolerance.
IgE mediated allergic reactions are characterized by
several different clinical manifestations that may involve
any kind of organ and develop few minutes or few hours
after food ingestion (usually within 2 hours). Acute sys-
temic reactions are caused by the activation of mas-
tocytes and basophils and consequent production of
chemical mediators. Oropharyngeal symptoms are usu-
ally represented by labial and palatal tinging and itching,
angioedema, hoarseness, dysphonia, dry cough. Gastro-
intestinal symptoms include nausea, vomit, cramps, colic
and diarrhoea. Other symptoms may be lacrimation and
nasal congestion, urticaria, other cutaneous manifesta-
tions, bronchospasm [16] and even anaphylaxis [16,17].
Non-IgE mediated food allergy is less common and
the cellular mechanisms involved in this type of hyper-
sensitivity are not completely understood yet. Clinical
manifestation are mainly characterized by acute and
chronic inflammation of the digestive tract or of the skin
that seem to result from an eosinophilic and T cell re-
sponse directly towards allergenic proteins, leading to
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matory response, with the involvement of specific cyto-
kines. These reactions have often a hereditary and ethnic
component, with a predisposition in caucasian male sub-
jects [1]. Clinical manifestation of non-IgE mediated dis-
orders include eosinophilic esophagitis; dietary-protein
induced enterocolitis (diarrhea, emesis, lethargy, poor
growth), that usually arises during childhood and later
undergoes resolution, and is often caused by milk, soy
and rice; dietary-induced proctitis (typical of childhood),
characterized by bleeding and mucilage in stools and
often associated to vaccine milk ingestion, besides sev-
eral other rare forms.
Some disorders are associated with a mixed IgE-/
cell-mediated reactions, such as atopic dermatitis,
eosinophilic gastroenteritis and eosinophilic esophagitis.
Oral tolerance is established in early childhood and
causes a suppression of local and systemic immune re-
sponse against food allergens and bacteria of endogenous
intestinal microflora. The organism may develop an effect-
ive immune response against foreign pathogens, but no re-
sponse is activated towards self-antigens. This condition,
defined as “specific immunologic hyporesposiveness”, de-
pends on an intact and immunological active gastrointes-
tinal barrier [1,18,19].
This barrier includes the epithelial cells joined by tight
junctions, mucosal layer, lumenal and brush border
enzymes, bile salts and extreme pH levels. Moreover, in-
testinal microflora plays a central role in the regulation
of gastrointestinal stability and physiology and in the
manteinance of an integrity of permeability of intestinal
mucosa. The increased permeability of intestinal mucosa
and early exposure to allergenic antigens have been pro-
posed as a possible cause of sensitization in infants. The
allergic response in sensitized subjects is a consequence
of the loss of oral tolerance and of the regulation of the
T cell response [18,20].Intestinal microflora and allergy
It is widely accepted that early exposure to environmen-
tal allergens may influence the maturation of the im-
mune system and the possible predisposition to develop
immune-mediated disorders such as autoimmune or
allergic disease [20].
The intestine, besides its digestive and absorbent activ-
ities, has a key role in the immune system as well. Part
of the intestinal barrier is composed by bacterial micro-
flora, which promotes intestinal physiology and provides
protection against external pathogens. Moreover, the gut
microflora is the most important source of microbial
stimulation and it plays a central role for the maturation
of the immune system and for the maintenance of gut
homeostasis.The human gastrointestinal tract (GI), at birth, is ster-
ile and the immune system is naїve. Soon after birth, GI
tract is colonised by numerous types of microorganisms,
and after approximately one week after birth the colon-
isation is complete. Intestinal epithelium in mammalian,
performs its physiological functions in a microbe rich
environment, while the microbes improve host defences.
Human intestinal micro flora is composed by Bacteroides,
Clostridia, Enterobacteria, Bifidobacteria and Lactobacilli,
with significant differences between breast-fed and formula-
fed newborns.
The postnatal period of a new human being is charac-
terized, from the microbiological point of view, by the
formation of a new ecosystem: the microflora of the hu-
man gut. While in adulthood a number of barriers exert
a potent selective action on bacteria arriving from the
mouth, in very first stage of life these barriers are at low
levels and feeding (breast vs bottle feeding) play a key
role in determining the microflora composition.
According to data obtained by means of classical
microbiological techniques, bifidobacteria, lactobacilli,
and other anaerobic bacteria appears to reach the gut
after 2–3 days.
An additional source of bacteria for the breast-fed neo-
nates is mother’s milk, which contains up to 109 microbes/L
in healthy mothers. The most frequently encountered bac-
terial groups include staphylococci, streptococci, cory-
nebacteria, lactobacilli, micrococci, propionibacteria and
bifidobacteria, originating from the nipple and surround-
ing skin as well as the milk ducts in the breast. Particularly
it has even suggested that human breast milk is a relevant
source of lactobacilli for newborn, overall L.acidophilus
followed by L.casei and L.paracasei, whereas babies with a
standard formula harboured mainly L.delbruekii and L.
reuteri, L.acidophilus however is also present in these
babies but at lower level.. In adult subjects, GI tract is
colonised by over 1014 microorganisms, and, so far, less
then 50% of the species of the gut micro flora have been
identified [20-22].
The interaction between microbiota and host organism
can be either symbiotic or commensal. The bacteria of
microbiota can facilitate both the absorption of nutrients
and the prevention of intestinal colonization by patho-
genic microrganisms.
Commensal microorganisms, acquired since the first
postnatal period, are required for the development of
immune tolerance, not only towards themselves, but also
to other antigens, such as food antigens. The interaction
with the commensal microflora of the GI tract is one of
the environmental signals that support T-cells (mainly
Th1) maturation. The tolerance to the microbiota is sup-
ported by the ability of commensal bacteria to suppress
inflammatory response (i.e. by down regulating the NK-
kB activity) and by absence of virulence factors ex-
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by Toll-like receptors (TLRs) on the surface of immune
system cells [23,24].
Over these past few years, industrialized countries
have outpointed a significant increase in autoimmune
and allergic diseases, which are considered to be related
by Th1- and Th2-mediated mechanisms, respectively.
The increase in immunologically mediated disorders
might be explained by an impaired maturation of the
immune function during the early stages of life, with a
consequent loss of immune tolerance. This mechanism
seems to be largely mediated by the microenvironment
of the intestinal mucosa and adjacent lymphoid tissues.
According to the “hygiene hypothesis” low or no ex-
posure to exogenous antigens in early life may increase
the risk of allergic diseases by both delaying the develop-
ment of the immune tolerance and limiting the Th2/Th1
switch. An altered microbial flora seems to allow the
persistence of Th2 cytokines (IL4, IL13, IL5), predomin-
ant at birth, and forbid the shift towards a predominant
Th1response, with production of IFN-g and IL12. How-
ever allergic diseases (Th1-mediated) and autoimmune
diseases (Th2-mediated), such as diabetes mellitus type
1 are not mutually exclusive [25]. This may suggest that
the hygiene hypothesis may oversimplified the immuno-
logic basis of allergic diseases.
The importance of commensal bacteria could also be
highlighted by the recent “old friends hypothesis” (a re-
vised version of the “hygiene hypothesis”), which claims
that the presence of these bacteria is crucial for the mat-
uration of regulatory dendritic cells, that promote T
regulatory cells (Tregs) differentiation through TGF-b
and IL-10 production. This mechanism is related to a
suppression of the inflammatory response against com-
mensal bacterial antigens, which then leads to the mat-
uration of an high number of regulatory dendritic cells,
to the processing of self or food antigens and to the
induction of immunological tolerance [26,27].
Recent studies on cell-based mechanisms of auto-
immune and allergic diseases have led to the discovery of
another T cell subset, Th17, which seems to have a role in
the pathogenesis of allergic diseases. IL-17 levels are in-
creased in asthmatic patients sputum and may contribute
to the pathogenesis of non-atopic and/or non-eosinophil
/neutrophil-dominant asthma [28-30]. Changes in the
symbiotic microflora may have a role in balance between
inflammatory Th17 cells and Tregs Foxp3+ cells operating
in the intestine [31].
The importance of microbiota for the regulation of im-
mune responses is supported by the observations of differ-
ent composition of intestinal microflora between allergic
and non-allergic children. Björksten et al., showed a high
prevalence of Staphylococcus Aureus and a lower percent-
age of Bacteroides and Bifidobacteria in allergic childrenat the age of 2 [32]. Another study has later confirmed
these results and showed a higher prevalence of Clostridia
in allergic children [33].
Early in life the immune system is immature and re-
quires stimuli from the environment, such as microbial
exposures, to mature properly. The gut microbiota com-
position has previously been reported to differ during
infancy prior to the development of allergic disease, im-
plying a role of the gut microbiota in promoting toler-
ance to harmless antigens through education of the
immune system. Bifidobacteria have been demonstrated
to have a species-specific influence on gut immunity,
and thus the early composition of bifidobacteria may
have a major impact on the naïve immune system. It has
been clearly demonstrate that breast-milk contains
bifidobacteria and that a constant supply of bifidobac-
teria to the infant’s intestine is thus assured during
breastfeeding. Allergic infants have indeed been found to
be colonized by bifidobacteria less often and with lower
concentrations. It is also noteworthy that B. adolescentis
is found more often in the intestinal microbiota in aller-
gic than in non-allergic children.
More recently, the bifidobacterial predominance in the
intestinal microbiota of breast fed infants has been linked
to the direct transfer of maternal bifidobacteria to new-
borns in breast-milk and consequently in promoting a
healthy intestinal microbiota, reducing the risk of atopic
diseases.
Even if there are many unclear aspects on cellular and
molecular interaction between the intestinal microflora
and the immune system, the importance of a correct
homeostasis of microbiota for reducing the risk to develop
an allergic disorder is widely accepted and the possible use
of probiotic strains, as a support therapy, is a central argu-
ment in the scientific debate.
Probiotics
The critical role of intestinal microbiota in the develop-
ment of immune tolerance improved recently the interest
on dietary supplements, as probiotics, that can promote
intestinal colonization and gut homeostasis.
The term “probiotic” derives from the Latin word
“pro” and the Greek word “bios,” meaning “for life”, and
is related to the concept of “probiotic”, probably intro-
duced by Elie Metchnikoff in 1907. He proposed the idea
that ingestion of live microbes could have beneficial effects
on human health. The definition of Metchnikoff includes
both the use of a food matrix fermented by beneficial bac-
terium and a “concentrated” bacterial supplementation in
the diet.
The definition of “probiotics” evolved over the years
and in 2001 a group of experts convened the currently
FAO/WHO definition of probiotics as “live microrganisms
which, when administered in adequate amounts, confer a
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Ministry of Health defined probiotics as “microrganisms
which, once ingested in adequate amounts, have benefi-
cial effects on the organism” [35].
The main characteristic of probiotics is the human ori-
gin of these bacterial strains, that is one of the criteria
for their selection. Moreover, to define a good probiotic,
several requirements are needed, such as: the ability to
adhere to gut epithelium cells, to exclude or reduce
pathogenic adherence, to persist, multiply and produce
acids, hydrogen peroxide and bacteriocins against patho-
genic growth. They are considered safe, non-invasive,
non-carcinogenic and non-pathogenic and are able to
aggregate to form a normal balanced microflora [36].
Probiotics consist in bacteria or yeast, able to re-
colonize and restore microflora symbiosis in intestinal
tract. Probiotic bacteria usually belong mainly to Lactoba-
cillus and Bifidobacterium groups, in particular Lactoba-
cillus acidophilus and Bifidobacterium bifidus, which
include different strains (L. rhamonusus, L. bulgaricus, L.
salivarius, L. plantarum, L. casei, B. infantis, B. longum,
Streptococcus thermophilus). Some common probiotics, as
Saccharomyces boulardii, are yeasts [37]. Several bacterial
strains are acid and bile tolerant and can be isolated from
the mammal gastrointestinal system.
Many positive effects have been attributed to pro-
biotics strains as an improvement of the GI tract
homeostasis and of digestion, a regularization of the in-
testinal bowel and a possible modulation of the immune
system.Safety of probiotics
One of the most important characteristics of probiotics is
their safety for human health, that is one of the crucial
points for their selection. In particular, the characteriza-
tion of a probiotic strain is based on the absence of resist-
ance to clinical or veterinary antibiobiotics as well as the
absence of virulence factors [38].
The Scientific Committee on Animal Nutrition of the
EU (SCAN), the EFSA panel on additives, products and
substances used in animal feed (FEEDAP) and the Italian
Ministry of Health recommended the verification of the
absence of transferable antibiotic resistant genes as a
prerequisite for approval of a microrganism [39,40].
The identification of bacterial strain is necessary not
only for safety reasons, but also to prove their efficacy
due to the fact that different strains of the same species
may exert different effects on the host [27].
The consumption of probiotics increased in recent
years and they are considered as “generally regarded as
safe” (GRAS), but many studies showed controversial
results about their safety and their efficacy in clinical
practice.The possible complications related to use of probiotics
could be the development of bacteriemia, sepsis or
endocarditis, the toxicity and the metabolic effects on
the GI tract and the possibility of transfer antibiotic
resistance to the GI flora, even if bacteriemia and
fungemia may occur rarely and are often related to the
use of saprophytic probiotics [38]. Moreover, some
probiotics bacteria showed negative characteristics as
the presence of virulence factors, possible acquisition of
virulence genes or antimicrobial resistance that can in-
duce unwanted resistance in endogenous bacterial popu-
lations [39].
Some probiotics strains, such as Lactobacillus, Leuconostoc,
Enterococcus and Bifidobacterium, have been isolated
from infected sites leading to the problem of a possible
translocation of these probiotics. Liong underlined that
probiotics translocation is a rare event in healthy humans,
but the possible damaging effects of probiotics transloca-
tion can occur in immunocompromised patients [40].
Several studies regarding the use of probiotics in critical
patients showed controversial results and further investi-
gation are required to better understand the mechanisms
of probiotic translocation and infection.
Probiotics and immunity
Thanks to their ability to adhere to intestinal epithelial
cells (IELs) and to modulate and stabilize the composition
of gut microflora, probiotics bacteria may play an import-
ant role in the regulation of intestinal and systemic
immunity. Probiotics may influence the functionality of
dendritic cells (DCs), NK cells, monocytes, macrophages
and, to a lesser extent, B cells.
The adhesion of some probiotics, in particular lactic
acid bacteria (LABs), to the epithelial intestinal wall pro-
mote their capture in the Peyer’s patches, where they
directly modulate both activation and proliferation of
DCs. Probiotics are able to stimulate both IL-10 and IL-
12 production by myeloid DC (mDCs), that promote
Th1-Th2/Treg polarization, and TNF-a and IL-6 by
DCs. Several LABs also induce DCs maturation through
the induction of IL-12 and TNF-a production and pro-
mote IFN-a production by plasmacytoid DCs (pDCs).
Mature DCs are potent activators of NK cells, through
cytokines production, as IL-12 and IL-15, that induce
NK cell activation, proliferation and cytotoxic activity.
Some probiotics strains are also able to stimulate mono-
cytes to produce IL-12 and NK cells for the production
of IFN-g [41-43].
The ability of LABs to shape NK/DCs crosstalk and to
directly stimulate NK activation highlights the importance
of some probiotics strains in promoting NK-dependent
IFN-g production, and thereby Th1 polarization. The
presence of LABs in early life may be useful to promote
Th1 polarization and prevent Th2-mediated disorders.
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after recognition of the whole bacterial cell or of bacter-
ial components eg. PPRs by several surface receptors
expressed on innate and acquired immune cells, called
toll-like receptors (TLRs). These active molecules are
DNA and cell wall components, such as unmethylated
CpG DNA (ligand of TLR9), peptidoglycan, lipoteichoic
acid and lipopolysaccharides (ligands of TLR2, TLR1 and
TLR4). The activation of TLRs, after recognition of bac-
terial antigens, leads to cell maturation, and cytokine
production and proliferation [43-45].
The activation of DCs promotes T cells response and
IL-10 and IL-12 production, making a linkage between
microbiota, innate immunity and adaptative immunity.
Specific probiotics strains may induce directly a B cells
response, increasing humoral immunity, and T cells re-
sponse, increasing cell-mediated immunity. In particular,
in the intestinal lamina propria, B cells differentiate in
plasma cells producing dimeric IgA antibodies. Secretory
IgA are released into the intestinal lumen, where they have
a crucial role in the mucosal immunity, after the binding
with a specific transporter receptor on basolateral surface
of intestinal epithelial cells [46,47]. An experimental study
showed that the administration of a mixture of Lactobacil-
lus casei, L. acidophilus, L. rhamnosus, L. delbrueckii subsp.
bulgaricus, Streptococcus salivarius subsp. thermophilus
and Lactococcus lactis had positive effects on the respira-
tory system by preventing and reducing respiratory infec-
tions due to an increase of IgA-secreting cells in bronchial
mucosa in mice [48].
Probiotics and allergy
It is well known that the intestinal mucosa microenvir-
onment plays a crucial role in the maturation of the im-
mune system since birth. In particular, the balance
between Th1 and Th2 immune response and the induc-
tion of immune tolerance is regulated in the gut by the
interaction of microflora bacterial antigens and immune
cells.
The conclusion that changes in the composition of the
gut microbiota are implicated in the pathogenesis of
allergic disorders has increased the attention of re-
searchers on the use of probiotics in order to treat and/
or prevent allergic diseases [49,50]. Clinical studies on
allergic patients yielded to controversial results over the
efficacy of probiotics as an anti-allergic treatment.
Many studies focused on the use of probiotics strains
for atopic dermatitis and other cutaneous allergic mani-
festations. The disruption of the skin barrier initiates the
subsequent atopic march that might lead to allergic air-
ways diseases: in fact, children affected by atopic derma-
titis are more prone to develop allergic asthma [51-54].
The first report by Majama et al., showed a modest re-
duction of atopic dermatitis in children after one monthof treatment with L. rhamnosus and a concomitant re-
duction of TNF-a and a1-AT in feaces of children after
probiotic consumption, when compared to the placebo
group [55]. However, no effect was detected regarding
systemic immune responses [56].
The idea of a strict correlation between the compos-
ition of intestinal microflora and the predisposition of al-
lergic diseases is supported by several observations of
changes in intestinal microbiota of atopic children with
a high prevalence of Clostridia [57-59]. These studies
reinforce the hypothesis of a role of probiotics in the re-
currence of allergic respiratory symptoms in children.
An Italian study conducted in 2007 on a cohort of 187
pre-school children (119 with asthma, 131 with allergic
rhinitis and 63 with both) with allergic symptoms to air-
borne allergens showed that the consumption of
fermented milk containing L.casei DN-114 001 reduced
of 33% the recurrence of yearly rhinitis with a two times
lower incidence in children receiving probiotics com-
pared to the placebo group. Moreover, the genetic ana-
lysis of intestinal microflora performed in a subgroup of
45 patients showed a high prevalence of L.casei DN-114
001 and other probiotic strains in the patients group
compared to controls; the colonization of the GI tract
persisted for 6–12 months in almost all subjects [60].
The different composition of the intestinal microflora
in allergic children suggests that the immediate modifi-
cation of post-natal colonization could be useful to pre-
vent allergic diseases. Kalliomäki et al., proposed the
administration of probiotics during pregnancy and in the
early post-natal period. They reported a reduction of
50% of infantile eczema [61]. The same group also re-
ported that the administration of Lactobacillus GG to
both mothers and infants during the firs 6 months post
partum had positive effects in preventing the appearance
of early atopic diseases in children at high risk, with a
marked reduction of asthma and eczema, if compared to
the placebo group [62].
This study paved the way to many subsequent re-
searches on the use of different probiotic strains to treat
and prevent allergic diseases, but, unfortunately, the
results seem controversial and inconsistent [63]. In par-
ticular, Kopp et al. reported that Lactobacillus GG sup-
plementation in pregnant women and early infants was
not effective in reducing either the incidence of atopic
dermatitis or the severity of the disease in affected chil-
dren, but it was associated with an increased incidence
of episodes of wheezing [64].
Moreover, a recent meta-analysis made a compari-
son between several studies conducted from 2001 and
2009 on probiotic consumption during pregnancy and
early life. The meta-analysis showed that administra-
tion of lactobacilli in pregnant women could be useful
in preventing atopic dermatitis in children from 2 to
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biotic strains does not affect the development of atopic
dermatitis [66-70].
The effects of a mixture of different probiotic strains
have been investigated by Kukkonen et al. in a random-
ized double blind controlled trial in a cohort of pregnant
women, who assumed during 2 to 4 weeks before deliv-
ering a mixture of Lactobacillus rhamnosus GG(ATCC
53103), L rhamnosus LC705 (DSM 7061), Bifidobac-
terium breve Bb99(DSM 13692), and Propionibacterium
freudenreichii ssp. shermanii JS(DSM 7076) containing
galacto-oligosaccharides (GOS). Probiotic treatment did
not reduce the incidence of IgE-associated diseases in
children by the age 2 years, but significantly prevented
the development of atopic dermatitis [71].
Another recent study demonstrated the absence of effi-
cacy of Lactobacillus rhamnosus to change the compos-
ition of gut microflora. The consumption of a probiotc
preparation by 50 women during late pregnancy did not
affect the composition of intestinal microflora of infants
after 7 days of breast feeding, compared to control
group [72].
The usefulness of probiotics not only for prevention,
but also as a therapeutic support for allergy is not com-
pletely demonstrated, and the results remain controver-
sial. Many studies focused on the use probiotics in the
treatment of atopic dermatitis. A randomized placebo-
controlled trial showed the efficacy on adult atopic pa-
tients of Lactobacillus salivarius LS01 after 16 weeks of
supplementation. LS01 was associated with an improve-
ment of skin manifestations, a significant reduction of
Staphylococci in feaces of the probiotic group and
modulation of Th1/Th2 cytokine profile [73].
The use of probiotic strains in therapy against allergic
disease has been widely investigated and it has been
hypothesized that the therapeutic potential of these bac-
terial strains decreases with increasing age due to the
completion of intestinal colonization and the establish-
ment of allergic phenotype. A great number of studies
mainly focused on therapeutic use of probiotics during
the paediatric age, in particular during infancy and early
childhood.
Recently the effect of supplementation of formulated
milk with Lactobacillus paracasei CNCM I-2116 or
Bifidobacterium lactis CNCM I-3446 has been investi-
gated in infants at 3–6 months of age affected by atopic
eczema, compared to placebo (fed with an hydrolysed
whey-formula). The researchers showed no benefit in
the treatment of eczema after supplementation with L.
paracasei or B. lactis and no effects on progression of
allergy from 1 to 3 years [74,75].
Frequently the use of combinations of probiotics and
prebiotics (synbiotics) showed beneficial effects. Wu et al.
reported that the supplementation with a synbiotic[Lactobacillus salivarius and fructo-oligosaccharide (FOS)]
had positive effects in 60 paediatric atopic patients aged
2–14 years affected by severe to moderate atopic derma-
titis. The group treated with the combination of Lactoba-
cillus salivarius and FOS showed a significant reduction of
atopic dermatitis after 8 weeks of treatment compared to
the group treated with only FOS [76].
Moreover we previously evaluated the efficacy of a mix-
ture of Lactobacillus paracasei I 1688, Lactobacillus
salivarius I 1794 (PSMIX) after 30 days treatment in paedi-
atric patients affected by atopic dermatitis. The probiotic
preparation was well tolerated and induced regularization
of intestinal function. Even if only one patient referred a
significant improvement of atopic dermatitis, “in vitro”
immunological investigations showed an increase in Th1
immune response, as in the IL-12 and IL-10 cytokine pro-
duction, in CD4+ T cell response and in Natural Killer
activity. These results confirmed a previous report on
“in vitro” immunomodulatory effects of the two bacterial
strains and their mixture in PBMCs (peripheral blood
mononuclear cells) of healthy volunteers [77,78].
The efficacy of probiotics in the treatment of allergic
respiratory diseases has not been completely demon-
strated, due to the relative paucity of studies in this field.
Asthma and respiratory allergic may occur in paediatric
age, but most studies have been conducted on adults,
who present a more established intestinal microflora and
more established patterns of immune response; in this
group, probiotics seem to be less effective [79]. In young
children (6–24 months) with recurrent wheeze and an
atopic family history, oral Lactobacillus GG supplemen-
tation had no positive effects on asthma or atopic
dermatitis and only mild effects on allergic sensitization
for the following 6 months [80]. A recent study with a
mouse model of allergic asthma showed that oral admin-
istration of L. gasseri attenuated allergen-induced airway
inflammation and induced a reduction in IL 17-mediated
immune response [81].
Few studies, conducted on animal models, focused on
the evaluation of the efficacy of probiotics in the preven-
tion and treatment of food allergy, with controversial re-
sults. Lactococcus lactis NCC 2287 oral administration
for 7 weeks in sensitized mice reduced allergic mani-
festation and “in vitro” production of IL-12, CCL11 and
CCL17 in the ileum, compared to control mice [82]. An
“in vitro” study showed that oral administration of a pro-
biotic mixture containing 8 different strains (Lactobacillus
acidophilus, L. delbrueckii subsp. bulgaricus, L. casei, L.
plantarum, Bifidobacterium longum, B. infantis, B. breve,
Streptococcus salivarius subsp. thermophilus) could have
beneficial effects in ovalbumin-sensitized mice, with a re-
duction in symptoms severity and a down regulation of
Th2 cytokine mRNA expression, in particular IL-13, IL-4
and IL-5 in the jejunum [83].
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efficacy in the prevention and treatment of allergy may
be due to the great heterogeneity of strains, duration of
therapy and doses used. Even if there are promising data
on the treatment of atopic dermatitis, little is known
about the efficacy of probiotics for respiratory allergic
symptoms and food allergy [84,85].
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